Your Health Magazine Contributor
4201 Northview Drive
Suite 102
Bowie, MD 20716
More Supplements Articles
NMN in 2026: What Human Trials Show About NAD+ and Aging
What NMN Is and Why People Care About NAD+
Nicotinamide mononucleotide is a molecule your body uses to make NAD+, a coenzyme your cells need for energy production and DNA maintenance, among other jobs. NAD+ levels decline with age.
People take NMN to raise their NAD+ levels, and that part works. Human trials back it up consistently. What nobody’s nailed down is whether having more NAD+ in your blood translates to anything you’d notice in daily life.
Blood NAD+ Goes Up
Yi et al. (2023) ran a randomized, placebo-controlled trial with 80 healthy middle-aged adults. Participants took placebo or 300, 600, or 900 mg of NMN daily for 60 days. All three dose groups saw significantly higher blood NAD+ than placebo, with the 600 mg and 900 mg groups showing the largest gains. The study also reported improved six-minute walk distance. One caveat: an NMN raw material supplier funded the study, and several authors were company employees.
Pencina et al. (2023) used a higher dose in 30 overweight or obese adults aged 45 and older: 1,000 mg twice daily, totaling 2,000 mg, for 28 days. NAD+ levels rose substantially. A smaller open-label study by Yamaguchi et al. (2024) found NAD+ increased in immune cells of 11 middle-aged men at 250 mg daily for eight weeks, though that was single-arm with no placebo.
I’d call this the least debated claim about NMN. In these three trials, every dose tested raised blood NAD+.
Insulin and Metabolism
The most cited metabolic result comes from Yoshino et al. (2021), published in Science. Twenty-five postmenopausal women who were overweight or obese and had prediabetes took 250 mg of NMN daily for 10 weeks. Muscle insulin sensitivity and insulin signaling pathways both improved; the placebo group didn’t change. I think the finding is genuine (good journal, clean design), but it’s one trial in prediabetic women, and extending it to generally healthy people or men is something the data can’t support yet.
The 2026 meta-analysis by Yang et al. pooled 15 randomized controlled trials. Fasting glucose, HbA1c, and HOMA-IR didn’t reach statistical significance across the board. There was a non-significant downward trend in insulin resistance. Body weight and BMI didn’t move either.
Blood Pressure
Pencina’s 28-day trial found diastolic blood pressure dropped 7.01 mmHg at 2,000 mg daily, which looks striking until you remember the sample was 30 people over four weeks.
Zhang et al. (2026) ran a meta-analysis of 10 trials covering 349 participants. Diastolic pressure fell by 2.15 mmHg (95% CI: −3.68 to −0.61). Statistically significant but clinically small. Systolic pressure didn’t change overall, though adults over 60 showed a 3.94 mmHg drop in a subgroup analysis.
The authors called their own findings “preliminary and suggestive.” I’d agree. If you need to manage blood pressure, proven medications exist for that.
NMN Didn’t Build Muscle
Prokopidis et al. (2025) published a systematic review and meta-analysis of NMN and NR trials in older adults with a mean age of 60.9 to 83 years. No significant effect on skeletal muscle index, grip strength, gait speed, or sit-to-stand time. I’d push back hard on any product label that claims NMN builds muscle or strength. Even less evidence exists for younger people.
Kim et al. (2022) tested 108 older Japanese adults over 12 weeks and found all four groups, including placebo, improved on sit-to-stand.
How Safe Is NMN So Far?
Yang et al.’s 2026 meta-analysis examined safety across 10 trials. Adverse events, serious adverse events, and liver enzymes (ALT and AST) weren’t increased compared to placebo.
That’s reassuring for the short term. But 24 weeks is the longest any trial has run — nobody’s published five-year safety data. I wouldn’t pretend we know what happens past that.
Does Time of Day Matter?
Kim et al.’s 12-week trial split 108 older adults into four groups: morning NMN, afternoon NMN, morning placebo, and afternoon placebo. The NMN groups took 250 mg once a day; the placebo groups took placebo. The afternoon NMN group had the largest effect sizes for sit-to-stand performance (d = 0.72) and drowsiness reduction (d = 0.64). But the afternoon placebo group’s drowsiness also improved, making it hard to separate an NMN effect from an afternoon-dosing effect.
That’s a single study with four arms and no clear winner for NMN specifically. I wouldn’t rearrange your day around this, and if your doctor suggests a dose, ask about timing too.
The Product Quality Problem
Sandalova et al. (2024) bought NMN and urolithin A products from online retailers and pharmacies, then measured the actual contents. Deviations from the label ranged from +28.6% to −100% across the products tested, and at least one product contained none of the labeled ingredient. That finding, to me, matters more than which dose any trial used.
Say a product claims 500 mg but delivers 200 mg; you won’t replicate any study’s results at that actual dose. A physician-reviewed comparison of NMN supplements covers what to check on a label and a certificate of analysis.
Where NMN Stands with the FDA
The FDA concluded in 2022 that NMN couldn’t be sold as a dietary supplement, arguing it had been authorized for drug investigation before it was marketed as a supplement. Three years later, the agency reversed course. Citizen petitions from the Natural Products Association, Alliance for Natural Health USA, and Council for Responsible Nutrition led the FDA to acknowledge NMN had been marketed as a supplement first, putting it back in the supplement category as of September 2025.
Niagen Bioscience (formerly ChromaDex), which sells nicotinamide riboside, sued the FDA in February 2026 to challenge the reversal; in May 2026, the FDA asked the court to dismiss for lack of standing. I haven’t seen a final ruling as of this writing, but NMN is sold legally as a dietary supplement in the United States for now.
Who Should Talk to a Doctor First
Don’t start NMN without medical advice if you:
- Are pregnant or breastfeeding
- Take medications for diabetes or blood pressure
- Have a history of cancer or are in treatment
- Have any chronic health condition
- Are under 18
If you’re on any prescription medication, I’d talk to your prescriber too. Very little interaction data has been published for NMN.
Where I’d Start
If you’re not already exercising, sleeping well, and eating a reasonable diet, those would do more for you than any supplement, and they have decades of outcome data to back them up. If you still want to try NMN after that, the FAQ below has dose details from the published trials.
Future trials might replicate one or two of these early metabolic signals, and NMN could earn a real place in the evidence base. Or it turns out to be expensive NAD+ elevation with no measurable clinical payoff. I’d spend accordingly. We probably won’t know for five to ten more years.
Common Questions
How fast does NMN raise NAD+ levels?
Most trials measured NAD+ after the full study period of 4 to 12 weeks. Pencina et al. found large increases after just 28 days at 2,000 mg daily. How quickly lower doses work hasn’t been well studied in humans.
Is NMN better than NR?
No head-to-head human trial has compared NMN and nicotinamide riboside on clinical outcomes. Both raise NAD+. The Prokopidis meta-analysis pooled NMN and NR data and found neither improved muscle mass, grip strength, or gait speed in adults averaging over 60. Without a direct comparison, picking between them comes down to price and product quality.
Can NMN reverse aging?
No human trial has shown that. Mouse studies get cited a lot, but rodent results don’t transfer automatically to people.
What dose should I take?
Human trials have tested 250 to 2,000 mg daily for up to 24 weeks. Yi et al. found the highest NAD+ increases and walk distance improvements at 600 and 900 mg compared to 300 mg. The only trial at 2,000 mg (Pencina et al.) lasted 28 days in 30 people, so longer-term data at that dose doesn’t exist. There isn’t enough evidence for anyone, myself included, to name an ideal number. Work it out with your clinician.
About the author:
Tao Wu is the founder of YourHealthier, a supplement company that sells NMN among other products. He has a commercial interest in NMN, which readers should consider when evaluating the views expressed here.
References
- Yi L et al. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience 2023;45(1):29-43. PMID: 36482258
- Yoshino M et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science 2021;372(6547):1224-1229. PMID: 33888596
- Pencina KM et al. Nicotinamide adenine dinucleotide augmentation in overweight or obese middle-aged and older adults: a physiologic study. J Clin Endocrinol Metab 2023;108(8):1968-1980. PMID: 36740954
- Kim M et al. Effect of 12-week intake of nicotinamide mononucleotide on sleep quality, fatigue, and physical performance in older Japanese adults: a randomized, double-blind placebo-controlled study. Nutrients 2022;14(4):755. PMID: 35215405
- Yamaguchi S et al. Safety and efficacy of long-term nicotinamide mononucleotide supplementation on metabolism, sleep, and nicotinamide adenine dinucleotide biosynthesis in healthy middle-aged Japanese men. Endocr J 2024;71(2):153-169. PMID: 38191197
- Prokopidis K et al. The effect of nicotinamide mononucleotide and riboside on skeletal muscle mass and function: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle 2025;16(3):e13799. PMID: 40275690
- Yang W et al. Safety and metabolism-related outcomes of oral nicotinamide mononucleotide supplementation in adults: a systematic review and meta-analysis. Nutrients 2026;18(14):2251. PMID: 42514320
- Zhang M et al. Effects of nicotinamide mononucleotide supplementation on blood pressure: a systematic review and meta-analysis of randomized controlled trials. Nutrients 2026;18(6):890. PMID: 41901064
- Sandalova E et al. Testing the amount of nicotinamide mononucleotide and urolithin A as compared to the label claim. GeroScience 2024;46(5):5075-5083. PMID: 38935229
Other Articles You May Find of Interest...
- NMN in 2026: What Human Trials Show About NAD+ and Aging
- How Liposomal Glutathione Can Support Active Lifestyles
- 5 Things to Know About Organic Beef Organ Supplements and Their Nutritional Value
- Fiber Supplements for Anal Fissures: Options and Precautions
- Herbal Products and Urinary Tract Health: What to Know About Detoxification Claims
- Glutathione Supplements: Comparing Ingredients, Formats and Price
- The Difference Between Magnesium Citrate and Magnesium Glycinate: What Parents Need to Know











